Molecular Partners AG MOLN
Annual
Quarterly
No annual revenue total was found in MOLECULAR PARTNERS AG's SEC filings.
Molecular Partners AG (MOLN) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances).
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
40.37M
+0.0% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- MOLN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Switzerland
- Headquarters
- Schlieren-Zurich, Switzerland
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1745114
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 29, 2026 | Sep 30, 2026 |
| 6-K | Current report (foreign issuer) | Aug 25, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | Jul 20, 2026 | Jul 16, 2026 |
| 6-K | Current report (foreign issuer) | Jul 7, 2026 | Jul 6, 2026 |
| 6-K | Current report (foreign issuer) | Jul 2, 2026 | Jul 2, 2026 |
| 6-K | Current report (foreign issuer) | Jun 1, 2026 | May 30, 2026 |
All 121 Molecular Partners AG SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.